NEWDIGS Design Lab
April 8–9 at Convene Boston
April 8–9, 2025
Convene Boston
201 Washington St, Floor 2, Boston 02108
Themes
- Provide final feedback on the Obesity Roadmap prior to its publication and roll-out.
- Share current projections, status of new financing tools (especially CMMI model), and best practices for Cell and Gene Therapy access.
- Transforming care for Alzheimer’s disease in the new era of disease-modifying therapies through interventions delivered in primary care.
Day 1
8:30 am – 7:30 pm
8:30 am – 9:30am
Registration & Networking Breakfast
9:30 am – 10:15am
Intros & Frame the day
Mark Trusheim, NEWDIGS
10:15 am – 10:45am
Obesity Roadmap Feedback
Elizabeth Paul, Obesity Action Coalition
Cristy Gallagher, STOP Obesity Alliance
Marc-Andre Cornier, Medical Univ. SC
Luke Prettol, AT&T
10:45 am – 10:50am
Breakout Instructions
Mark Trusheim
10:50 am – 12 pm
Breakouts
12 pm – 1 pm
Networking Lunch
1 pm – 2:15 pm
Report-outs
2:15 pm – 3:00 pm
CGT Updates
Jay Park, Core Clinical Sciences
Rebecca Metcalfe, Core Clinical Sciences
Sharon Phares, NEWDIGS
Katie Phillip, NEWDIGS
3:00 pm – 3:15 pm
Break
3:15 pm – 4:45 pm
Panel: Lessons Learned from CGT
Jane Barlow, NEWDIGS (Moderator)
Brian Carey, Hogan Lovells
Sarah Emond, ICER
Paul Jeffrey, Jeff℞ey Consulting
Kelly Maynard, Little Hercules Foundation
Nico Mros, Lyfegen
4:45 pm – 5:30 pm
Next Steps/Forward Planning
Mark Trusheim
Gigi Hirsch, NEWDIGS
5:30 pm – 7:30 pm
Networking Reception
Day 2
8:00 am – 2:15 pm
8:00 am – 9:00 am
Networking Breakfast
9:00 am – 9:15 am
Frame the day
Tom Hubbard, NEWDIGS
9:15 am – 10:05 am
Alzheimer’s Case Study
Case Study Team
Presentation and Clarifying Questions
10:05 am – 10:10 am
Breakout Instructions
Tom Hubbard
10:10 am – 11:25 am
Breakouts
11:25 am – 11:35 am
Break
11:35 am – 12:50 pm
Report-outs
12:50 pm – 1:15 pm
Wrap-up/Next Steps
Tom Hubbard
1:15 pm – 2:15 pm
Networking Lunch (to-go options available)
Design Lab participants
Annie Acs
Executive Director, Value Based Healthcare Policy
Eli Lilly & Co
Vicki Albrecht
Head of Commercial Strategy
Metsera
Faraz Ali
CEO
Tenaya Therapeutics, Inc
Shannon Armstrong
VP, Value and Access
Metsera
Azrina Azhar
Project Director
NEWDIGS
Jane Barlow
Senior Advisor
NEWDIGS
Amy Bassano
Managing Director, Medicare
Health Management Associates
David Bates
CEO
Linus Health
Matthew Baumgart
Senior Vice President, Health Policy
Alzheimer's Association
Michael Brown
Director, Alliance to Improve Dementia Care
Milken Institute
Amy Emmert
Executive Director for Cellular Therapy External Affairs
Dana-Farber Cancer Institute
Brian Carey
Partner
Hogan Lovells
Frank Casambre
Industry Research and Insights Manager
AffirmedRx
June Cha
Policy Director, FasterCures
Milken Institute
Elizabeth J. Cobbs
Senior Consultant
NEWDIGS
Laura Cohen
VP, Alzheimer’s Environment Shaping
Eli Lilly & Co.
Michael Collins
Senior Director, Global Pricing
Johnson and Johnson
Anthony Comuzzie
Chief Executive Officer
The Obesity Society
Christa Cormier
Assoc. Director, Marketing
Biogen
Marc-Andre Cornier
Professor/Director
Medical University of South Carolina
Terry Cothran
Senior Pharmacy Director
Oklahoma Health Care Authority
Gregory Daniel
Vice President, Global Public Policy
Eli Lilly & Co
Lucas de Breed
Founder
August
Brian Dunkin
Chief Medical Officer, Endoscopy (Global)
Boston Scientific
Sarah Emond
President and CEO
Institute for Clinical and Economic Review
Christine Gallagher
Associate Director for Research and Policy
STOP Obesity Alliance
John Glasspool
CEO
VarmX
Abhi Gupta
SVP, Cell & Gene Therapy
Syenos
Erin Hertzog
Partner
Manatt, Phelps & Phillips
Gigi Hirsch
Director, CBSD & NEWDIGS
Tufts Medical Center
Tom Hubbard
Senior Advisor
NEWDIGS
Ali Jannati
Director of Cognitive Science
Linus Health
Maureen Japha
Associate VP
Eli Lilly & Co.
Paul Jeffrey
Principal
Jeff℞ey Consulting
Andreas Klein
Interim Chief, Division Hem/Onc
Tufts Medical Center
Ian Kremer
Executive Director
LEAD Coalition
Betsy Ladyzhets
Content Writer
NEWDIGS
Kimberly Lenz
Chief Pharmacy Officer
MassHealth
Jim Leonard
Deputy Director Pharmacy Office
Colorado Dept. of Health Care Policy and Financing
Kate Lofgren
Chief Scientific Officer
Abett, Inc.
Peter Loupos
Founder and General Manager
Princeton Healthcare Strategies
Sonali Malhotra
Medical Director
AstraZeneca
Jackie Martin
VP, Market Access & Patient Services
Intellia Therapeutics
Rebecca Metcalfe
Principal Scientist
Core Clinical Sciences
Mark Monane
Chief Medical Officer
C2N Diagnostics
Joshua Moore
Director of Pharmacy
MO HealthNet (Missouri Medicaid)
Lisa Mostovoy
SVP, Next Gen Commercialization
Population Health Partners
Nico Mros
Chief Customer Experience Officer & Founder
Lyfegen
Joseph Nadglowski
President/CEO
Obesity Action Coalition
Shruti Nambiar
Head of HEOR
Intellia Therapeutics
Chuka Ndukauba
Senior Director, Strategy & Product
Optum
Marisha Palm
Assistant Professor
Tufts Institute for Clinical Research and Health Policy Studies
Jay Park
Scientific Lead
Core Clinical Sciences
Catherine Patterson
Director of Strategic Initiatives
UsAgainstAlzheimer's
Elizabeth Paul
Patient Advocate & Board Member
Obesity Action Coalition
Sharon Phares
Associate Director for Research
NEWDIGS
Katie Phillip
Research Associate
NEWDIGS
Adam Phipps
Associate Vice President, US Gov't Payer Strategy
Eli Lilly & Co
Cynthia Pigg
President
Pigg Insights
Anne Pohnert
Lead Director of Clinical Quality
CVS MinuteClinic
Ron Potts
CMO
6 Degrees Health
Luke Prettol
Principal Strategy Consultant
AT&T
Cassie Ricci
Senior Manager, Alliance Development
Roche Diagnostics
Caitlin Rivet
Executive Director Neurosciences & Behavioral Health
Tufts Medicine
Gail Ryan
Director of Pharmaceutical Transformation
Point32Health
Eric Small
Program Manager
NEWDIGS
Stephanie Tran
Associate Director
IPD Analytics
Mark Trusheim
Strategic Director
NEWDIGS
Dao Tu Xuan
Head of Global Access Strategy
Takeda Pharmaceuticals International
Diane Ty
Managing Director, Future of Aging
Milken Institute
Nick Vance
VP, Associate General Consul
Intellia Therapeutics
JK Wall
Senior Director of Neuroscience Communications
Eli Lilly & Co
Melonie Warfel
Global Head, Business Development
Lyfegen
Claire White
Cell Therapy Policy Analyst
Children's Hospital of Philadelphia
Brooks Wildasin
Chief Product and Innovation Officer
Havarti Risk
Julie Wood
SVP Science and Clinical Strategy
American Academy of Family Physicians
Abigail Wright
Director of Evidence Synthesis
Institute for Clinical and Economic Review
Briefing: Roadmap for Transforming Obesity Disease Management
Case study: Transforming Patient-centric Early Alzheimer's Disease Care
LocationConvene Boston |
Chatham House Rule
The Chatham House Rule is used in meetings where participants need a way to openly share information, but don't want to be identified as the source of that information in any meeting records or articles written afterward. The rule is invoked regularly in meetings dealing with sensitive topics. It reads:
“When a meeting, or part thereof, is held under the Chatham House Rule, participants are free to use the information received, but neither the identity nor the affiliation of the speaker(s), nor that of any other participant, may be revealed.”
Antitrust Compliance Statement
Updated November 8, 2022
Tufts Medical Center's NEWDIGS initiative spearheads initiatives focused on re-engineering drug development and delivery processes to optimize access to new medicines for patients while ensuring the sustainability of pharmaceutical innovation. Many of these initiatives involve cooperation among various constituencies, including pharmaceutical companies and other industry stakeholders, patient advocates, healthcare payers, and academic and research institutions.
Because competitors or potential competitors in the marketplace are often participating in the same initiatives, participants in NEWDIGS activities must take care to stay within antitrust boundaries.
The antitrust laws prohibit firms from entering into agreements and engaging in arrangements with competitors that are “anticompetitive” — meaning that they reduce competition more than they advance it. The antitrust laws, however, support and encourage “procompetitive” agreements and arrangements that increase efficiency, enable and improve innovation, and increase the availability of higher quality, lower cost goods and services. NEWDIGS’s initiatives are designed to facilitate “procompetitive” processes.
This Statement provides antitrust guidance to Tufts Medical Center personnel and to the representatives of companies and other institutions who participate in NEWDIGS activities with the goal of encouraging and ensuring antitrust compliance. Even for specially trained experts, it can sometimes be difficult to distinguish “anticompetitive” from “procompetitive” outcomes. This Statement articulates General Antitrust Principles that guide differentiation of various interactions and lists Specific Antitrust Guidelines to enhance the procompetitive nature of NEWDIGS activities and reduce the risk of any inadvertent violation of the antitrust laws. NEWDIGS asks all participants in NEWDIGS activities to follow the General Antitrust Principles and to adhere to the Specific Antitrust Guidelines. The Principles and the Guidelines are intended to be conservative – meaning that they will prohibit some conduct that the antitrust laws may allow – in order to provide a reasonable safety margin for everyone.
General Antitrust Principles
1. Be “antitrust aware”, including in your emails, documents, and conversations. This means remembering that no NEWDIGS activity is intended to reduce competition or create undesirable “anticompetitive” effects. These undesirable effects include increased market power, higher prices, lower quality goods or services, and the creation or strengthening of obstacles to innovation.
2. Part of being “antitrust aware” involves recognizing and memorializing, when appropriate, the desirable “procompetitive” effects that flow from cooperative exploration and innovation. These effects include faster rates of innovation, greater efficiency, increased output, lower prices, and higher quality goods and services. Documents and meeting agendas that identify those positive effects create a helpful contemporaneous record of the participants’ procompetitive vision, which can be consulted later.
3. Note that preserving a particular company’s or group of companies’ prices, profit margins, or position in an industry is not a legitimate goal, particularly in the dynamic industries involved in NEWDIGS’s activities. All companies are expected to succeed on their own merits and not because they have created obstacles to competition. The law establishes one important exception – patent holders possess a temporary, completely legal monopoly as their reward for innovation. A patent holder, acting alone, is entitled to use the legal system to exclude rivals from practicing the subject of the patent.
4. “Market power,” meaning the ability of a single company or group of companies to control the price or availability of goods and services, is rarely permissible under antitrust laws. The acquisition or use of market power is tolerated where it results from superior products, services, or business skill, but otherwise it is highly suspect. No NEWDIGS activity that makes economic sense only if it creates or intensifies market power for the participants (other than through the eventual assertion of patent rights) should be undertaken without first consulting NEWDIGS's compliance contact.
5. Other countries have their own competition regimes, and some of those regimes operate quite differently from the United States’ antitrust laws. Recognizing that much of NEWDIGS’s work may affect the global marketplace, NEWDIGS intends to comply with competition laws in all countries where its work has local effect. This Compliance Statement addresses the fundamental principles that are common to the competition regimes in the United States and the European Union. If you believe a NEWDIGS activity is likely to have a significant, negative economic effect on a company outside of the United States or European Union, please raise that issue with NEWDIGS's compliance contact.
Specific Antitrust Guidelines
1. Do not reach any of the following types of agreements with a competitor: agreements affecting the price at which goods or services are sold in competition; agreements allocating customers or markets among competitors; or agreements not to deal with any company or organization.
2. Do not discuss with a competitor information concerning any of the following: your company’s or your competitors’ prices, costs, discounts, terms of sale, or profit margins or anything else that might affect those prices; the resale prices your customers should charge for any products you sell them; markets, customers, territories, or products sold in competition; whether or not to deal with any other company or organization; or any other competitively sensitive information concerning your company or a competitor. In addition, do not share non-public data concerning these topics with a competitor.
3. Do prepare and follow an accurate agenda, even if only in summary form, for meetings attended by representatives of two or more direct competitors.
4. Do consult with NEWDIGS’s antitrust compliance contact before proceeding in any area of uncertainty. The compliance contact does not provide legal advice. When needed, the compliance contact will obtain legal advice for Tufts Medical Center participants. All non-Tufts Medical Center participants must consult their own counsel for legal advice.
5. Do recognize that the antitrust laws encourage cooperation among competitors for the legitimate, procompetitive purposes envisioned by NEWDIGS. A more detailed look at this complex area may be found in the United States’ Antitrust Guidelines for Collaborations among Competitors, found here.